73 related articles for article (PubMed ID: 578759)
1. Spironolactone metabolism in normal subjects and in patients with liver cirrhosis.
Váradi A; Fehér T; Bodrogi L; Koref O
Arzneimittelforschung; 1977; 27(8):1618-20. PubMed ID: 578759
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of a prednisolone compound in human under normal and pathological conditions.
Fehér T; Koref O; Tankó A; Bodrogi L; Poteczin E
Arzneimittelforschung; 1975 Aug; 25(8):1314-7. PubMed ID: 52365
[TBL] [Abstract][Full Text] [Related]
3. Attenuation by spironolactone of the magnesiuric effect of acute frusemide administration in patients with liver cirrhosis and ascites.
Stergiou GS; Mayopoulou-Symvoulidou D; Mountokalakis TD
Miner Electrolyte Metab; 1993; 19(2):86-90. PubMed ID: 8377729
[TBL] [Abstract][Full Text] [Related]
4. Dipyrone metabolism in liver disease.
Zylber-Katz E; Caraco Y; Granit L; Levy M
Clin Pharmacol Ther; 1995 Aug; 58(2):198-209. PubMed ID: 7648770
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of picumast dihydrochloride in patients with liver cirrhosis.
Neugebauer G; Raedsch R; Stiehl A; Kaufmann B; Besenfelder E; Neubert P; Walter-Sack I
Arzneimittelforschung; 1989 Oct; 39(10A):1343-7. PubMed ID: 2576360
[TBL] [Abstract][Full Text] [Related]
6. Disposition kinetics of spironolactone in hepatic failure after single doses and prolonged treatment.
Abshagen U; Rennekamp H; Luszpinski G
Eur J Clin Pharmacol; 1977 Mar; 11(3):169-76. PubMed ID: 856602
[TBL] [Abstract][Full Text] [Related]
7. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
[TBL] [Abstract][Full Text] [Related]
8. The effect of liver disease in man on the disposition of phenobarbital.
Alvin J; McHorse T; Hoyumpa A; Bush MT; Schenker S
J Pharmacol Exp Ther; 1975 Jan; 192(1):224-35. PubMed ID: 235636
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
Vergin H; Nuss U; Strobel K
Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
[TBL] [Abstract][Full Text] [Related]
10. A pharmacokinetic study on midazolam in compensated liver cirrhosis.
Rinetti M; Ascalone V; Colombi Zinelli L; Cisternino M
Int J Clin Pharmacol Res; 1985; 5(6):405-11. PubMed ID: 2936689
[TBL] [Abstract][Full Text] [Related]
11. Biotransformation and uric acid lowering effect of benzbromarone in patients with liver cirrhosis - evidence for active benzbromarone metabolites?
Walter-Sack I; de Vries JX; von Bubnoff A; Pfleilschifter V; Raedsch R
Eur J Med Res; 1995 Oct; 1(1):16-20. PubMed ID: 9392688
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status.
Zapater P; Lasso de la Vega MC; Horga JF; Such J; Frances R; Esteban A; Palazòn JM; Carnicer F; Pascual S; Pérez-Mateo M
Aliment Pharmacol Ther; 2004 Jul; 20(1):29-36. PubMed ID: 15225168
[TBL] [Abstract][Full Text] [Related]
13. Oral and intravenous pharmacokinetics of cimetidine in liver cirrhosis.
Okolicsanyi L; Venuti M; Orlando R; Lirussi F; Nassuato G; Benvenuti C
Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):482-7. PubMed ID: 7141756
[TBL] [Abstract][Full Text] [Related]
14. Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test.
Saudek F; Morávek J; Modr Z
Int J Clin Pharmacol Ther Toxicol; 1989 Feb; 27(2):82-7. PubMed ID: 2921099
[TBL] [Abstract][Full Text] [Related]
15. Serum metabolite/caffeine ratios as a test for liver function.
Jodynis-Liebert J; Flieger J; Matuszewska A; Juszczyk J
J Clin Pharmacol; 2004 Apr; 44(4):338-47. PubMed ID: 15051740
[TBL] [Abstract][Full Text] [Related]
16. [Metabolism of hexobarbital in patients with acute hepatitis and cirrhosis (author's transl)].
Richter E; Gallenkamp H; Keller B; Brachtel D; Zilly W; Breimer DD
Z Gastroenterol; 1977 Jun; 15(6):381-8. PubMed ID: 888488
[TBL] [Abstract][Full Text] [Related]
17. Comparison of azosemide and furosemide in ascitic patients without and during administration of spironolactone.
Radó JP; Molnár Z; Hartai A; Gercsák G
Int J Clin Pharmacol Ther Toxicol; 1982 Nov; 20(11):532-7. PubMed ID: 7174156
[TBL] [Abstract][Full Text] [Related]
18. Oxmetidine (SK&F 92994): pharmacokinetic study in patients with in patients with liver cirrhosis.
Miglio F; Baraldini M; Serra S; Facchini A; Stefanini GF; Meliconi R; Gasbarrini G; Labo' G
Int J Clin Pharmacol Res; 1985; 5(6):399-404. PubMed ID: 2869000
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
[TBL] [Abstract][Full Text] [Related]
20. Temazepam clearance unaltered in cirrhosis.
Ochs HR; Greenblatt DJ; Verburg-Ochs B; Matlis R
Am J Gastroenterol; 1986 Jan; 81(1):80-4. PubMed ID: 2867675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
